drugset / Trial / NCT07647510
A Phase 3 Study to Evaluate Claseprubart in Adults With Generalized Myasthenia Gravis (EMERGE)
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this Phase 3 study is to demonstrate the efficacy, safety, and tolerability of claseprubart in participants with generalized myasthenia gravis (gMG).
Timeline
- Start
- 2026-07
- Primary completion
- 2028-12
- Completion
- 2031-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Claseprubart | Unknown | — | Intravenous |